Amygdala Neurosciences is a biopharmaceutical company focused on addressing the large (and growing) - but unmet - need associated with substance use disorders. Development programs addressed by the firm include treatment of opioid, nicotine, alcohol and cocaine use disorders. The company's technology uses a selective ALDH2 inhibitor that prevents a surge in dopamine levels -- and the associated cravings -- without changes to basal dopamine. This has the effect of enabling patients to quit and get rid of their addiction to drugs, alcohol, and smoking. In addition to their SBIR involvement, the firm has successfully secured substantial related funding from NIH and DOD
